Journal ArticleDOI
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Hossein Ardeschir Ghofrani,Hossein Ardeschir Ghofrani,Gérald Simonneau,Gérald Simonneau,Andrea Maria D'Armini,Peter F. Fedullo,Luke Howard,Luke Howard,Xavier Jaïs,Xavier Jaïs,David P. Jenkins,Zhi-Cheng Jing,Michael M. Madani,Nicolas Martin,Eckhard Mayer,Kelly Papadakis,Dominik Richard,Nick H. Kim,Irene Lang,Christian M. Kähler,Marion Delcroix,Zoheir Bshouty,Pablo Sepulveda Varela,Yuanhua Yang,Jin-Ming Liu,Gang-Cheng Zhang,Nuofu Zhang,Yuhong Mi,Xian-Yang Zhu,Pavel Jansa,Grégoire Prévot,Hélène Bouvaist,Olivier Sanchez,Friedrich Grimminger,Matthias Held,Heinrike Wilkens,Stephan Rosenkranz,Ekkehard Grünig,Kristóf Karlócai,András Temesvári,Istvan Edes,Sigita Aidietienė,Skaidrius Miliauskas,Tomas Rene Pulido Zamudio,Carlos Jerjes Sanchez,Anton Vonk Noordegraaf,Jerzy Lewczuk,Piotr Podolec,Jarosław Kasprzak,Tatiana Mularek-Kubzdela,Ryszard Grzywna,Keertan Dheda,Olga Moiseeva,Alexander Chernyavskiy,Vladimir M. Shipulin,Olga Barbarash,Tamila Vitalievna Martynyuk,Hyung Kwan Kim,Jun Bean Park,Jae Seung Lee,Rudolf Speich,Silvia Ulrich,John-David Aubert,Arintaya Phrommintikul,Nattapong Jaimchariyatam,Suree Sompradeekul,Zeynep Pinar Onen,Gulfer Okumus,Lyubomyr Solovey,Volodymyr Gavrysyuk,Luke S. Howard,Joanna Pepke-Zaba,Robin Condliffe,John McConnell,Kim M. Kerr,Lan Hieu Nguyen,Nguyen Vinh Pham +76 more
Reads0
Chats0
TLDR
In MERIT-1, macitentan significantly improved PVR in patients with inoperable CTEPH and was well tolerated, and resting PVR at week 16, expressed as percentage of PVR measured at baseline.About:
This article is published in The Lancet Respiratory Medicine.The article was published on 2017-10-01. It has received 189 citations till now. The article focuses on the topics: Macitentan & Placebo-controlled study.read more
Citations
More filters
Journal ArticleDOI
Does combination therapy work in chronic thromboembolic pulmonary hypertension
TL;DR: Long-term overall survival of CTEPH patients receiving PH-specific medial therapy is very reasonable, and combination therapy showed similar survival as monotherapy.
Journal ArticleDOI
Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension
TL;DR: The 16-week Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Study 1 (CHEST-1) study was the first to operationalize learnings, demonstrating a significant mean improvement in 6-minute walk distance and improvements in hemodynamic endpoints with riociguat versus placebo.
Journal ArticleDOI
Distal vessel pulmonary thromboendarterectomy: Results from a single institution.
Timothy M. Fernandes,Nick H. Kim,Kim M. Kerr,William R. Auger,Peter F. Fedullo,David Poch,Jenny Yang,Demosthenes G. Papamatheakis,Mona Alotaibi,Melissa A. Bautista,Victor Pretorius,Michael M. Madani +11 more
TL;DR: In this paper , the most proximal level of chronic thromboembolic pulmonary hypertension (CTEPH) resection (Level I (main pulmonary artery), Level II (lobar), Level III (segmental) and Level IV (subsegment) were compared to distal disease (Level III or IV bilaterally).
Journal ArticleDOI
Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis
TL;DR: In this article, the authors compared all of the PAH-targeted medications that are used to treat chronic thromboembolic pulmonary hypertension and rank their efficacy by the application of network meta-analysis.
Journal ArticleDOI
Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial
Kazuya Hosokawa,Kohtaro Abe,Junji Kishimoto,Yuko Kobayakawa,Koji Todaka,Yuichi Tamura,Koichiro Tatsumi,Takumi Inami,Nobutaka Ikeda,Yu Taniguchi,Shun Minatsuki,Toyoaki Murohara,Satoshi Masuda,Keiichi Fukuda,Hiroyuki Tsutsui +14 more
TL;DR: The KABUKI trial is an investigator-initiated, multicentre, phase 3, randomised, single-blind, parallel-group, warfarin-controlled, non-inferiority trial to evaluate the efficacy and safety of edoxaban versus warfar in (vitamin K Antagonist) in subjects with chronic thromboembolic pulmonary hypertension.
References
More filters
Journal ArticleDOI
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
Nazzareno Galiè,Marc Humbert,Jean-Luc Vachiery,Simon Gibbs,Irene Lang,Adam Torbicki,Gérald Simonneau,Andrew Peacock,Anton Vonk Noordegraaf,Maurice Beghetti,Ardeschir Ghofrani,Miguel Angel Gomez Sanchez,Georg Hansmann,Walter Klepetko,Patrizio Lancellotti,Marco Matucci,Theresa McDonagh,Luc Pierard,Pedro T. Trindade,Maurizio Zompatori,Marius M. Hoeper +20 more
TL;DR: In this paper, the authors defined the following terms: ALAT, alanine aminotransferase, ASAT, aspartate AMINOTE, and APAH, associated pulmonary arterial hypertension.
Journal ArticleDOI
Special article2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension
Nazzareno Galiè,Marc Humbert,Jean-Luc Vachiery,Simon Gibbs,Irene Lang,Adam Torbicki,Gérald Simonneau,Andrew J. Peacock,Anton Vonk Noordegraaf,Maurice Beghetti,Ardeschir Ghofrani,Miguel Angel Gomez Sanchez,Georg Hansmann,Walter Klepetko,Patrizio Lancellotti,Marco Matucci,Theresa McDonagh,Luc Pierard,Marius M. Hoeper +18 more
TL;DR: This article is being published concurrently in the European Heart Journal and the European Respiratory Journal and is identical except for minor stylistic and spelling differences in keeping with each journal’s style.
Journal ArticleDOI
Inhaled iloprost for severe pulmonary hypertension.
Horst Olschewski,Gérald Simonneau,Nazzareno Galiè,T. Higenbottam,Robert Naeije,Lewis J. Rubin,Sylvia Nikkho,Rudolf Speich,Marius M. Hoeper,Jürgen Behr,Jörg Winkler,Olivier Sitbon,Wladimir Popov,H. Ardeschir Ghofrani,Alessandra Manes,David G. Kiely,R Ewert,Andreas Meyer,Paul A. Corris,Marion Delcroix,Miguel Ángel Gómez-Sánchez,Harald Siedentop,Werner Seeger +22 more
TL;DR: Inhaled Iloprost is an effective therapy for patients with severe pulmonary hypertension and hemodynamic values were significantly improved at 12 weeks when measured after iloprost inhalation, and were significantly worse in the placebo group.
Journal ArticleDOI
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Tomás Pulido,Igor Adzerikho,Richard N. Channick,Marion Delcroix,Nazzareno Galiè,Hossein Ardeschir Ghofrani,Pavel Jansa,Zhi-Cheng Jing,Franck-Olivier Le Brun,Sanjay Mehta,Camilla Mittelholzer,Loïc Perchenet,B.K.S. Sastry,Olivier Sitbon,Rogério Souza,Adam Torbicki,Xiaofeng Zeng,Lewis J. Rubin,Gérald Simonneau +18 more
TL;DR: Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.
Journal ArticleDOI
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Hossein Ardeschir Ghofrani,Andrea Maria D'Armini,Friedrich Grimminger,Marius M. Hoeper,Pavel Jansa,Nick H. Kim,Eckhard Mayer,Gérald Simonneau,Martin R. Wilkins,Arno Fritsch,Dieter Neuser,Gerrit Weimann,Chen Wang +12 more
TL;DR: Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension.
Related Papers (5)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
Nazzareno Galiè,Marc Humbert,Jean-Luc Vachiery,Simon Gibbs,Irene Lang,Adam Torbicki,Gérald Simonneau,Andrew Peacock,Anton Vonk Noordegraaf,Maurice Beghetti,Ardeschir Ghofrani,Miguel Angel Gomez Sanchez,Georg Hansmann,Walter Klepetko,Patrizio Lancellotti,Marco Matucci,Theresa McDonagh,Luc Pierard,Pedro T. Trindade,Maurizio Zompatori,Marius M. Hoeper +20 more
Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry.
Marion Delcroix,Irene Lang,Joanna Pepke-Zaba,Pavel Jansa,Andrea Maria D'Armini,Repke J. Snijder,Paul Bresser,Adam Torbicki,Søren Mellemkjær,Jerzy Lewczuk,Iveta Simkova,Joan Albert Barberà,Marc de Perrot,Marius M. Hoeper,Sean Gaine,Rudolf Speich,Miguel Ángel Gómez-Sánchez,Gabor Kovacs,Xavier Jaïs,David Ambroz,Carmen M. Treacy,Marco Morsolini,David P. Jenkins,Jaroslav Lindner,Philippe Dartevelle,Eckhard Mayer,Gérald Simonneau +26 more
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Results From an International Prospective Registry
Joanna Pepke-Zaba,Marion Delcroix,Irene Lang,Eckhard Mayer,Pavel Jansa,David Ambroz,Carmen M. Treacy,Andrea Maria D'Armini,Marco Morsolini,Repke J. Snijder,Paul Bresser,Adam Torbicki,Bent Bruun Kristensen,Jerzy Lewczuk,Iveta Simkova,Joan Albert Barberà,Marc de Perrot,Marius M. Hoeper,Sean Gaine,Rudolf Speich,Miguel Ángel Gómez-Sánchez,Gabor Kovacs,A. Hamid,Xavier Jaïs,Gérald Simonneau +24 more